Key takeaways
- • Humana is predominantly a Medicare Advantage and Part D insurer, so most members face the federal Part D statutory exclusion on weight-loss drugs.
- • Wegovy (CVD) and Zepbound (OSA) may be covered under some Humana Part D formularies for their non-weight-loss FDA indications; verify with your specific plan.
- • T2D GLP-1s like Ozempic and Mounjaro are generally covered for type 2 diabetes with documentation and prior authorization; verify with your formulary.
- • Humana's smaller commercial and employer book follows standard PBM rules; self-funded ASO plans set their own anti-obesity benefit design.
- • Compounded semaglutide and tirzepatide are not FDA-approved finished products and are not covered by Humana plans.
How Humana approaches GLP-1 coverage
Humana's GLP-1 coverage depends on the line of business. Most Humana members are in Medicare Advantage Prescription Drug (MA-PD) or stand-alone Part D plans, where federal law statutorily excludes drugs used for weight loss. Wegovy, Zepbound, and Saxenda are therefore typically not covered when prescribed solely for obesity. A narrow exception exists for GLP-1s with FDA-approved non-weight-loss indications — Wegovy for cardiovascular risk reduction (SELECT, 2024) and Zepbound for moderate-to-severe obstructive sleep apnea (2024) — which individual Humana Part D formularies may elect to cover, subject to prior authorization.\n\nFor T2D GLP-1s (Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza), Humana generally includes them on Part D and commercial formularies for type 2 diabetes with documented diagnosis, A1C history, and often step therapy. Humana's smaller commercial and employer book uses standard tiered formularies, PA, and quantity limits, though self-funded ASO employer plans set their own benefit design. Verify with your specific plan and current year formulary.
Statutory and structural notes
Medicare Part D statutorily excludes "agents when used for anorexia, weight loss, or weight gain" under the Medicare Modernization Act of 2003 and Social Security Act §1860D-2(e)(2)(A). CMS guidance (April 2024) confirmed Part D plans may cover GLP-1s for medically accepted non-weight-loss indications such as Wegovy for CVD risk reduction and Zepbound for OSA. ACA Marketplace plans and self-funded ERISA employer plans are not required to cover anti-obesity medications.
Typically considered for coverage
The list below reflects general patterns observed across Humanaplan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.
- Ozempic for type 2 diabetes with documented diagnosis and prior auth — may be considered for coverage; verify with your specific plan and current formulary
- Mounjaro for type 2 diabetes with A1C documentation and typical step therapy — may be considered for coverage; verify with your specific plan and current formulary
- Rybelsus (oral semaglutide) for type 2 diabetes — may be considered for coverage; verify with your specific plan and current formulary
- Trulicity and Victoza for type 2 diabetes on certain Humana Part D and commercial tiers — may be considered for coverage; verify with your specific plan and current formulary
- Wegovy for cardiovascular risk reduction in adults with established CVD and overweight/obesity, on plans that elect to cover the SELECT indication — may be considered for coverage; verify with your specific plan and current formulary
- Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, on plans that elect to cover the OSA indication — may be considered for coverage; verify with your specific plan and current formulary
Typically excluded
- Wegovy, Zepbound, and Saxenda when prescribed solely for weight loss under Humana Medicare Advantage Part D or stand-alone Part D plans (federal statutory exclusion)
- Off-label use of T2D GLP-1s (Ozempic, Mounjaro) for weight loss without a documented diabetes diagnosis
- Compounded semaglutide and tirzepatide — not FDA-approved as finished products and not covered by Humana commercial or Part D plans
- GLP-1 use in patients who do not meet plan-specific BMI, A1C, or comorbidity criteria
- Coverage for indications outside the FDA label or outside CMS-recognized compendia for Part D
Prior authorization
Prior authorization is commonly required for GLP-1 medications under Humana plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.
Appeal strategy if denied
Humana members can request a coverage determination, then a Level 1 redetermination, followed by an Independent Review Entity (IRE) appeal for Part D; commercial members follow standard internal appeal then external review. Submit chart notes, A1C, BMI, comorbidities, prior therapy failures, and cite the specific FDA non-weight-loss indication (CVD or OSA) where applicable. Verify timelines with your specific plan documents.
GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.